EPA Replaces Animal Testing With 3D Human Tissue for Household Cleaning Products

On August 27, 2026, the U.S. Environmental Protection Agency (EPA) fundamentally altered how the chemicals under American sinks are vetted for safety. Moving away from live-animal inhalation studies, the agency announced it will now rely on lab-grown, three-dimensional human airway tissue to evaluate surfactants—the active compounds that give soaps, detergents, and household cleaners their grease-cutting power.[1][2][3]

Surfactants work by lowering the surface tension of water, allowing it to mix with oils and dirt. However, when aerosolized in household cleaning sprays, these same chemical properties can irritate the human respiratory tract. Historically, regulators measured this risk by exposing mammals to the aerosolized chemicals in laboratory settings.[1][5]

Under the new framework, the EPA will instead apply the formulas to 3D human airway models. These structures are built from actual human cells and are designed to mimic the biological responses of the human lung. By observing how these lab-grown tissues react to chemical exposure, reviewers can safely estimate inhalation risks using existing digital models rather than ordering new animal studies.[1][2]

EPA Administrator Lee Zeldin stated that this tissue-based approach allows regulators to assess hazards faster while reflecting human biology more accurately than traditional animal exposures. “EPA is leading the way on eliminating animal testing by embracing cutting-edge, gold standard science like never before,” Zeldin said.[1][4]

The August 27 announcement also included a second major scientific advancement: the adoption of the Globally Harmonized System (GHS) mixtures equation. This international, mathematically backed formula allows the agency to predict the oral toxicity of certain pesticide formulations without testing the final blended product on animals.[1][3]

The decision to adopt the GHS equation followed a comprehensive joint analysis conducted by the EPA and the National Institute of Environmental Health Sciences. Researchers evaluated nearly 700 distinct pesticide formulations, demonstrating that the calculation models can reliably assess risk profiles based solely on the known toxicity of the individual ingredients.[1][4]

These two integrated solutions represent a significant step toward the EPA's broader mandate. Following statutory amendments to the Toxic Substances Control Act in 2016, the agency outlined a formal directive in 2019 to phase out all mammalian study requests and funding over a 16-year timeline, targeting the year 2035.[2][4]

The August 2026 rollout builds on an expanded list of non-animal alternatives the agency released roughly 60 days earlier in June 2026. The shift toward New Approach Methodologies (NAMs)—a class of technologies that includes cell cultures, computer modeling, and shared data networks—has drawn support from both chemical manufacturers and animal welfare advocates.[1][5]

Tracie Letterman, Vice President of Federal Affairs for the Humane World Action Fund, noted the dual benefits of the policy. “Today's announcement is further evidence of EPA's ongoing commitment to phase out animal tests and replace them with better tools to predict human responses to chemicals and pesticides and their impact on the environment,” Letterman said.[1]

While the new frameworks cover surfactants and certain pesticide mixtures, they do not constitute a blanket policy change for all chemical reviews. New active ingredients still generally require a core battery of toxicological studies, some of which continue to involve animal testing where no validated digital or tissue-based alternative yet exists. The speed at which external researchers and chemical companies will adopt these new waiver mechanisms and submit non-animal data remains the next critical variable in the agency's 2035 timeline.[1][5]

The transition away from in vivo testing is accelerating globally. Just one day prior, on August 26, 2026, the United Kingdom government announced a £22 million investment to fund cutting-edge alternatives to animal testing. That initiative includes a £20 million center dedicated to growing miniature organs from human tissue and £2 million distributed across nine distinct projects, signaling a coordinated international shift toward digital and cell-based chemical safety models.[7]